Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

@article{Vergnengre2016EconomicAO,
  title={Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.},
  author={Alain Vergnen{\`e}gre and Bartomeu Massut{\'i} and Filippo de Marinis and Enric Carcereny and E Felip and Pascal D{\^o} and Jose Miguel Couselo S{\'a}nchez and Luis Paz-Arez and Christos Choua{\"i}d and Rafael Rosell},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2016},
  volume={11 6},
  pages={801-7}
}
INTRODUCTION The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal growth factor receptor gene (EGFR)-mutated advanced-stage non-small cell lung cancer (NSCLC) is poorly documented. We therefore conducted a cost-effectiveness analysis of first-line treatment with erlotinib versus standard chemotherapy in European patients with… CONTINUE READING